Actinium Pharmaceuticals (ATNM) Shares Up 5.1%

Shares of Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) shot up 5.1% during trading on Monday . The stock traded as high as $0.65 and last traded at $0.62. 877,465 shares changed hands during mid-day trading, an increase of 6% from the average session volume of 824,285 shares. The stock had previously closed at $0.59.

Several brokerages have commented on ATNM. Zacks Investment Research lowered shares of Actinium Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, December 3rd. Oppenheimer set a $5.00 price objective on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, February 26th. Maxim Group set a $3.00 price objective on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, February 5th. Finally, Roth Capital set a $6.00 price objective on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 4th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $3.55.

Get Actinium Pharmaceuticals alerts:

A number of large investors have recently bought and sold shares of the business. Virtu Financial LLC grew its position in shares of Actinium Pharmaceuticals by 103.1% during the 3rd quarter. Virtu Financial LLC now owns 195,623 shares of the biotechnology company’s stock valued at $146,000 after acquiring an additional 99,318 shares during the period. Vanguard Group Inc. grew its position in shares of Actinium Pharmaceuticals by 6.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after acquiring an additional 154,403 shares during the period. Vanguard Group Inc grew its position in shares of Actinium Pharmaceuticals by 6.4% during the 3rd quarter. Vanguard Group Inc now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after acquiring an additional 154,403 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Actinium Pharmaceuticals by 23.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,031,210 shares of the biotechnology company’s stock valued at $399,000 after acquiring an additional 198,480 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of Actinium Pharmaceuticals by 1,269.5% during the 2nd quarter. Renaissance Technologies LLC now owns 387,500 shares of the biotechnology company’s stock valued at $248,000 after acquiring an additional 359,205 shares during the period.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/4197207/actinium-pharmaceuticals-atnm-shares-up-5-1.html.

Actinium Pharmaceuticals Company Profile (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older.

Further Reading: Closed-End Mutual Funds (CEFs)